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Chile does not have a national registry of immunohematologic test 
results; there are no data on the prevalence of erythrocyte antigens 
and the frequency of antibodies in this population. Therefore, 
foreign references are used for decision-making. In this study, a 
standard questionnaire was used in 74 laboratories of public and 
private establishments. The information from tests conducted 
in 2015 was requested: ABO and D typing, antibody detection, 
antibody identification, and erythrocyte phenotype. Prevalence 
for the ABO-D phenotypes were obtained at the country level 
(D+ [94.4%] and D– [5.5%]) and differ from those recorded in the 
white population (85% and 15%, respectively). Positive antibody 
detection results were found in 0.4 and 1.3 percent of blood 
donors and patients, respectively; the main specificities were 
anti-Lea, -E, and -D in donors and anti-D, -E, and -K in patients. 
Inconclusive results were observed in ABO-D typing and antibody 
identification in donors and patients; these samples were referred 
to immunohematology reference laboratories for resolution. 
From this study, it was possible to estimate the prevalence of 
erythrocyte antigens and the frequency of antibodies at the 
national level, and this step allows us to characterize Chile’s 
population of blood donors and transfusion recipients and to 
compare the results and frequencies with other populations or 
countries. Immunohematology 2021;37:151–156. DOI: 
10.21307/immunohematology-2021-024.
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Transfusion medicine safety is guaranteed by quality 
management of trained human resources; adequate reagents 
and equipment; quality control in the pre-analytical, analyti-
cal, and post-analytical stages; and alignment with established 
reference standards. In transfusion therapy, there are norms 
and reference standards, such as those promoted by the AABB, 
which has established the importance of infectious disease 
and immunohematologic testing to guarantee the safety of 
the blood provided by a donor and transfused into a patient 
recipient.1
Pre-transfusion tests performed on donors and recipients 
in blood services are as follows: ABO and D typing, antibody 
detection, antibody identification, crossmatch, erythrocyte 
phenotype, and direct antiglobulin test.2
Currently, Chile does not have a national registry of 
immunohematologic test results that provide the prevalence 
of erythrocyte antigens and frequencies of antibodies in the 
national population. Therefore, decisions in public health and 
the design of policies for the transfusion process must use 
data from foreign bibliographic references, such as the AABB 
and the International Society of Blood Transfusion (ISBT), 
assuming that these data are similar to that found in Chile. 
The literature indicates that in white individuals, there is a 
prevalence of 85 percent of D+ individuals and 15 percent 
of D– individuals.1 In contrast, according to data obtained 
from Chilean national blood centers, the prevalence of D– 
individuals is just over 5 percent of the population in Chile.
Another example is the distribution of group O individuals 
in the white population—approximately 44 percent. In compari-
son, in some studies in different localities within Chile, group 
O is found at higher prevalence: 68.9 percent in Elqui, 67.2 
percent in Limarí, 56.5 percent in Choapa, 57.8 percent in 
Santiago, and 86.8 percent in the Mapuche population.3,4 On 
the other hand, some blood services in Chile use data from 
their patients and donors to establish their protocols, which 
is undoubtedly a contribution to the established data but does 
not represent the national reality.
In this context, the Public Health Institute of Chile 
(Instituto de Salud Pública de Chile) convened blood services 
through an online platform to collect information on 
immunohematologic testing in the country, both public and 
private, to establish reliable statistics and epidemiologic data 
for use in generating data for health decision-making.
Materials and Methods
In this study, we obtained data from the laboratories 
associated with the External Quality Assessment Program 
(Programa de Evaluación Externa de la Calidad) of Immuno-
hematology during 2016. From a total of 311 laboratories, both 
public and private, we selected those registered with the ABO-
RhD Blood Classification program as a base and at least one 
of the following subprograms: Detection and Identification 
of Irregular Antibody, Crossmatching, Direct Antiglobulin 
Test, and Phenotyping of Erythrocyte Antigens. Using these 
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criteria, 159 participating laboratories 
were selected: 4 national blood centers, 
51 blood banks, 40 transfusion medicine 
units, and 64 clinical laboratories.
A standard questionnaire was 
sent to these laboratories between 
January and March 2017 using the 
online platform “Registry of Immuno-
hematological Indicators in the Chilean 
Population.” This questionnaire was 
completed by a professional (medical 
technologist or physician) who had access 
to the platform through a username and 
pass-word previously sent via email. 
We collected information for 
the year 2015 (January–December) 
on the following topics: ABO and D 
typing, antibody detection, antibody 
identification, and erythrocyte pheno-
type. The information provided by the 
participants was analyzed using Excel 
spreadsheets. The ABO and D discrepant 
result data corresponded to all cases in 
which the participating laboratories were 
unable to establish ABO and D typing 
results, and the inconclusive results 
corresponded to all cases in which the 
identification of irregular antibodies was 
not achieved.
Results
Of the 159 establishments invited 
to participate, we received information 
from 74 laboratories (46.5%) (Fig. 1). 
The number and type of participating 
laboratories were as follows: 47 public 
establishments (4 blood centers, 17 
transfusion medicine units, 8 blood 
banks, and 18 clinical laboratories) and 
27 private establishments (3 transfusion 
medicine units, 15 blood banks, and 9 
clinical laboratories).
ABO-D Typing
A total of 73 laboratories provided 
data for ABO-D typing, and these 
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Fig. 1 Geographic distribution of immunohematology laboratories participating in the study.
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laboratories performed 791,217 tests. The absolute and 
relative prevalence for the different blood groups are detailed 
in Table 1. For ABO typing, the results were as follows: group 
O in 473,921 (59.9%), group A in 227,780 (28.8%), group B 
in 73,361 (9.3%), and group AB in 16,001 (2.0%) individuals. 
The D typing showed D+ in 747,236 tests (94.4%) and D– in 
43,827 tests (5.5%). The discrepant tests reported for ABO 
were 97 and for D were 57.
Antibody Detection and Identification
A total of 26 laboratories provided data for antibody 
detection testing in blood donors, reporting a total of 260,346 
tests. Negative results were observed in 259,252 (99.6%) and 
positive results in 1094 (0.4%) tests. A total of 64 laboratories 
provided antibody detection information for patients, reporting 
250,861 tests. Negative results were observed in 247,647 
(98.7%) and positive results in 3214 (1.3%) tests.
Table 2 shows the frequencies of alloantibodies detected in 
donors and patients included in the study establishments. From 
1094 positive detection tests in blood donors, 591 antibodies 
were identified in 11 participating laboratories; the main 
specificities were anti-Lea (20.5%), anti-E (18.3%), and anti-D 
(16.4%). Thirty-four combinations of irregular antibodies 
and 346 inconclusive antibody results were reported for 
blood donors. Among 3214 positive detection test results for 
patients, 1528 antibodies were identified in 25 participating 
laboratories; the main specificities were anti-D (25.8%), anti-E 
(23.6%), and anti-K (21.6%). A total of 39 combinations of 
irregular antibodies and 449 inconclusive antibody results for 
patients were reported.
Erythrocyte Phenotype
For antigen typing, a total of seven laboratories reported 
3055 tests for the Rh antigens (D, C, c, E, e), 1043 for the Kell 
antigens (K, k), 309 for the Duffy antigens (Fya, Fyb), and 361 
for the Kidd antigens (Jka, Jkb).
The Rh phenotypes mostly found in this study were DCe 
(21.8%), ce (20.7%), DCce (19.4%), and DCcEe (19.0%). In the 
Kell system, the K–k+ phenotype stands out (96.7%); in the 
Duffy system, the Fy(a+b+) phenotype stands out (46.0%); 
and in the Kidd system, the Jk(a+b+) phenotype stands 
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Table 1. Country distribution of the ABO-D typing results of the participating establishments in the study
O A B AB Discrepant
D+ D– D+ D– D+ D– D+ D– ABO D Total
n* 447,866 26,055 214,878 12,902 69,486 3875 15,006 995 97 57 791,217
%† 56.6 3.29 27.16 1.63 8.78 0.49 1.9 0.13 0.012 0.007
*Number of immunohematologic test results.
†Percentage of immunohematologic test results.
Table 2. Frequency of irregular red blood cell antibodies detected 




Antibody n* %† n %
MNS Anti-M 71 12.0 28 1.8
Anti-N 1 0.2 3 0.2
Anti-S 13 2.2 31 2.0
Anti-s 0 0 1 0.1
P1PK Anti-P1 7 1.2 2 0.1
Rh Anti-D 97 16.4 394 25.8
Anti-C 16 2.7 42 2.7
Anti-E 108 18.3 361 23.6
Anti-c 15 2.5 44 2.9
Anti-e 6 1.0 20 1.3
Lutheran Anti-Lua 6 1.0 7 0.5
Anti-Lub 0 0 1 0.1
Kell Anti-K 78 13.2 330 21.6
Anti-k 0 0 3 0.2
Anti-Kpa 1 0.2 5 0.3
Anti-Kpb 0 0 1 0.1
Anti-Jsb 0 0 1 0.1
Lewis Anti-Lea 121 20.5 125 8.2
Anti-Leb 5 0.8 8 0.5
Duffy Anti-Fya 20 3.4 55 3.6
Anti-Fyb 1 0.2 15 1.0
Kidd Anti-Jka 18 3.0 46 3.0
Anti-Jkb 0 0 5 0.3
Diego Anti-Dia 6 1.0 0 0
Xg Anti-Xga 1 0.2 0 0
Total 591 1528
*Number of immunohematologic test results.
†Percentage of immunohematologic test results.
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out (50.4%). All results are consistent with the prevalence 
described in international references of the ISBT5 and the 
AABB1 (Table 3).
Discussion
These results represent a first approximation of the 
prevalence of erythrocyte antigens and frequency of antibodies 
in the Chilean population, being the first study with significant 
coverage of public and private establishments in Chile.
Based on 791,217 tests, absolute and relative prevalence 
were obtained for the different ABO-D blood types at the 
country level, with the highest prevalence being group O for 
the ABO system, as seen in most of the world populations.1 
Concerning the Rh system, it was established that D+ 
is present in 94.4 percent and D– in 5.5 percent of our 
population. This finding identifies the Chilean population as 
closer to the prevalence of D in Hispanic individuals than in 
white individuals.1 In a study carried out at the University of 
Talca (Maule Region, Chile), there were already antecedents 
establishing the prevalence of D+ (96%) and D– (4%) in blood 
donors from the region.6
Positive antibody detection test results were observed 
in 0.4 percent of blood donors and 1.3 percent of patients. 
Previous records in Chile established positive results in 
0.23 percent of blood donors from Santiago,7 0.83 percent 
of patients from Concepción,7 and 1.02 percent of patients 
from Temuco.8 The main specificities of irregular antibodies 
were anti-Lea (20.5%), anti-E (18.3%), and anti-D (16.4%) in 
donors and anti-D (25.8%), anti-E (23.6%), and anti-K (21.6%) 
in patients. These results are similar to those reported in the 
different groups and localities of Chile: anti-Lea (24.4%), anti-K 
(18.5%), and anti-E (18.5%) were found in Santiago7; anti-D 
(27.3%), anti-E (21.4%), and anti-K (16.7%) were found in 
Concepción7; and anti-E (30.8%), anti-K (26.9%), and anti-D 
(7.7%) were found in Temuco.8
Our data cannot establish whether the frequency of 
anti-D in our study population is attributed to transfusions 
or pregnancy. However, it is estimated that transfusions may 
be responsible for the high frequency of anti-D observed in 
patients, since, in Chile, there are ministerial regulations to 
prevent alloimmunization to D in D– pregnant women through 
periodic immunohematologic testing during the pregnancy. 
In turn, the detection of weak and partial variants of D in 
donors, patients, and pregnant women is carried out through 
molecular methods, such as sequence specific–polymerase 
chain reaction. Data on hemolytic disease of the fetus and 
newborn in Chile have been established in some studies with 
current findings of 1–6.8 cases per 1000 live births and a 
mortality of 1.6 cases per 100,000 live births.
National guidelines in Chile establish antibody detection 
testing in blood donors and patients.9,10 In this study, we 
obtained data on the antibody detection test results in 
both blood donors and transfusion recipients because it is 
interesting to characterize both groups. For example, in other 
studies, the prevalence of irregular antibodies in blood donors 
was characterized by the presence of anti-D, anti-E, and 
Table 3. Distribution of the erythrocyte phenotypes of the Rh, Kell, 




phenotype n* %† ISBT AABB
Rh DCce 592 19.4 34.9 —
DCe 666 21.8 18.5 —
DCcEe 580 19.0 13.3 —
Dce 41 1.3 2.1 —
DcEe 279 9.1 11.8 —
DcE 146 4.8 2.3 —
DCEe 33 1.1 0.2 —
DCcE 6 0.2 0.1 —
DCE 4 0.1 0.01 —
ce 633 20.7 15.1 —
Cce 45 1.5 0.8 —
cEe 27 0.9 0.9 —
CcEe 3 0.1 0.5 —
Total Rh  3055 100.0   
Kell K–k+ 1009 96.7 — 91
K+k+ 34 3.3 — 8.8
Total Kell  1043 100.0   
Duffy Fy(a+b–) 99 32.0 — 20
Fy(a+b+) 142 46.0 — 48
Fy(a–b+) 68 22.0 — 32
Total Duffy  309 100.0   
Kidd Jk(a+b–) 61 16.9 — 26
Jk(a+b+) 182 50.4 — 50
Jk(a–b+) 118 32.7 — 24
Total Kidd  361 100.0   
Total 4768 — — —
*Number of immunohematologic test results.
†Percentage of immunohematologic test results.
ISBT = International Society of Blood Transfusion.
IMMUNOHEMATOLOGY, Volume 37, Number 4, 2021 155
Erythrocyte antigens and antibodies in Chile
anti-K (United States)11; anti-M and anti-D (India)12; anti-P1, 
anti-Lea, and anti-Leb (Laos)13; and anti-M, anti-Lea, and 
anti-D (Colombia).14 This latest study resembles the findings 
of our research, with a higher prevalence of anti-Lea in blood 
donors. This finding can be explained by the evidence that 
anti-Lea can be generated in people of Le(a–b–) phenotype 
naturally by viral or bacterial stimuli, transfusion history, 
and previous pregnancies.5,13,14 However, the prevalence of the 
Le(a–b–) phenotype in the Chilean population is not known, 
which is estimated to be between 6 and 25 percent in different 
ethnicities.1,5,15
Irregular antibody findings in patients receiving blood 
transfusions (%) is widely documented for different path-
ologies. For example, in a study of 153 polytransfused patients 
in Minas Gerais, Brazil, a higher frequency of anti-E (21.87%) 
and anti-K (21.87%) was observed.16 Another study of 227 
polytransfused patients in Sao Paulo, Brazil, reported the 
highest findings to be anti-E (22.06%), anti-D (13.18%), and 
anti-K (11.75%).17 Meanwhile, in a study of 152 transfused 
patients from Medellín, Colombia, it was observed that 
the vast majority of antibodies in the samples could not 
be identified (23.68%), followed by the presence of anti-E 
(17.10%), autoantibodies (11.18%), and anti-K (10.53%).18 Our 
study reported inconclusive results in 346 donor samples and 
449 patient samples, corresponding to a significant number 
of unresolved cases in the national network, leading to the 
establishment of periodic guidelines and training to ensure the 
identification of irregular antibodies in donors and patients.7
The erythrocyte phenotype study is considered a necessary 
tool to implement in immunohematology laboratories. Those 
patients who need red blood cell (RBC) transfusions receive 
compatible, phenotype-matched units for antigens in blood 
systems with antibodies of known greater clinical significance. 
In Chile, although there is no explicit legislation that establishes 
the implementation of erythrocyte phenotyping, a progressive 
increase has been seen in health establishments that have 
begun the implementation of providing Rh- and K-matched 
RBC units to patients who require multiple transfusions and 
therefore might develop alloimmunization (data obtained from 
the external quality assessment program, the Erythrocyte 
Antigen Phenotyping subprogram of the Public Health 
Institute of Chile).
The Rh phenotypes mostly found in this study were 
DCe (21.8%), ce (20.7%), DCce (19.4%), and DCcEe (19.0%). 
These findings are similar to the phenotypes in the white 
population considered referential.5 There are other studies in 
Chile that establish the highest prevalent phenotypes as DCe 
(32.5%), DCce (25.0%), and DCcEe (18.5%), which are also 
related to the results of our study.6 However, the ce phenotype 
finding was considerably higher than that of D– (5.5%) found 
in the RhD blood classification at the national level. This 
finding is probably explained by the fact that the erythrocyte 
phenotype studies in our country are not a routine procedure 
in establishments but are intended for targeted studies of the 
Rh phenotype in individuals.
In the Kell blood group system, a high prevalence (96%) 
of the K–k+ phenotype could be observed; this finding has 
already been described in the study by Vásquez et al.6
The erythrocyte phenotypes and alleles have already 
been studied in Chile’s coastal populations, allowing the 
authors to estimate the genetic trunk and the degree of inter-
breeding of the people of that region.19 The authors point 
out that there are allelic characteristics described in South 
American aboriginal populations, such as the high frequency 
of the ABO*O, FY*A, and JK*B alleles and the prevalence of 
the DCe and DcE haplotypes. All these genetic characteristics 
of our population were observed to identify the erythrocyte 
antigens in this study.
It was possible to determine the inconclusive results in 
the ABO typing, D typing, and antibody identification results 
in donors and patients, which must be resolved with new 
methodologies or referred to the national immunohematology 
reference laboratory.
From these data, each health establishment may have in-
formation that contributes to managing the quality assurance 
system on transfusion medicine issues. Relevant topics, such 
as knowing the relative prevalence of D– individuals in our 
country and identifying the principal clinically significant 
irregular antibodies in the work routine for donors and 
patients, provide data that support decision-making to ensure 
the quality of transfusion therapy to patients who require it.
This study provided the most extensive report on the 
results of immunohematology tests in the Chilean population 
to date; data on immunohematology tests were obtained 
from 46.5 percent of the laboratories and blood services that 
answered the survey. These results provided information 
regarding the characteristics of the population served, 
contributing to decision-making or planning centers that 
perform immunohematology tests at the country level, most 
notably ABO-D typing, antibody detection, and antibody 
identification in donors and patients, and crossmatch testing. 
Indeed, these tests are the immunohematologic basis that 
ensures the quality of blood transfusions, and the mandatory 
execution of these tests is subject to national regulations.
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As for erythrocyte antibodies, the most prevalent 
specificities could be identified in blood donors and transfusion 
recipients; this information is relevant for use as a national 
reference and can be applied in each immunohematology 
laboratory that performs antibody identification and provides 
RBC units for transfusion.
This work aims to strengthen the network of laboratories 
that perform immunohematologic tests and thus establish 
a surveillance system for immunohematology processes 
in Chile. It is estimated that the calculated prevalence 
and frequencies for erythrocyte antigens and antibodies, 
respectively, may better represent the Chilean population as 
the number of laboratories reporting their presence increases.
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